U
3.40
-0.35 (-9.22%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Unicycive Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -1.1 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.97 |
|
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 4.93% |
| 机构持股比例 | 49.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| J. Goldman & Co Lp | 30 Jun 2026 | 327,345 |
| Diadema Partners Lp | 30 Jun 2026 | 303,676 |
| Dauntless Investment Group, Llc | 30 Jun 2026 | 214,000 |
该时间范围内无数据。
该时间范围内无数据。
投资组合